What Does Agilent Technologies (A) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters at a Glance
Agilent Technologies (A) is a global company specializing in life sciences, diagnostics, and applied analytical instruments, characterized by stable recurring revenue from reagents and services and consistent capital returns. A summary of A's stock price, outlook, earnings, related stocks, and revenue.
🏢 What Kind of Company Is Agilent Technologies?
Agilent Technologies (A) is a global analytical instruments specialist headquartered in Santa Clara, California, USA, spun off from its former parent company in 1999. It supplies a broad range of analytical instruments, reagents, software, and services across pharmaceutical, biotech, food, environmental, and clinical diagnostics markets.
It operates liquid and gas chromatography, mass spectrometry, spectroscopy, clinical diagnostics reagents, genetic analysis instruments and reagents, analytical software, and global services businesses. It holds a leading position in the global analytical instruments group and runs a business model that combines instruments, reagents, and services.
💰 How Does Agilent Technologies Make Money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| Life Sciences & Applied Markets | Core | Chromatography, spectroscopy, and consumables |
| Diagnostics & Clinical | Key Growth Pillar | Clinical diagnostics reagents and platforms |
| CrossLab Services | Diversification Pillar | Recurring revenue from services and consumable reagents |
| Other & Software | Complementary Business | Analytical software |
The instruments segment accounts for a large share of revenue, while the reagents and services segment provides stable recurring revenue and margin stability. Pharmaceutical and biotech R&D investment, clinical diagnostics demand, and food, environmental, and semiconductor analysis demand serve as the key drivers of revenue flow. The cumulative installed base of instruments underpins structural growth in reagents and services revenue, and the expansion of countries with new product launches also functions as a complementary growth pillar.
📐 Agilent Technologies Market Cap and Company Scale
Market capitalization is $39.6B, and the employee count is 18,100명.
A life sciences instruments specialist positioned in the upper tier of global analytical instruments and diagnostics groups by market cap, it is benchmarked alongside analytical instruments and life sciences peers including TMO, DHR, WAT, BIO, and MTD. Backed by stable free cash flow and recurring reagents and services revenue, it continues a capital return policy of steady dividend increases and share buybacks.
📈 Agilent Technologies Outlook and Stock Price Trends
Recovery in global pharmaceutical and biotech R&D investment, growth in the clinical diagnostics market, expansion of demand for advanced therapeutics analysis, and growth in food, environmental, and semiconductor analysis markets are the medium- to long-term growth drivers. Rising attach rates of reagents and services and expansion into global emerging markets also function as complementary growth pillars. In the short term, volatility factors include fluctuations in the pharmaceutical and biotech capital investment cycle, China market variables, and FX volatility, while new product and pricing competition with analytical instruments rivals must also be monitored as short-term variables.
- Pharmaceutical & biotech R&D recovery
- Clinical diagnostics market growth
- Rising reagents & services attach rate
⚔️ Agilent Technologies Core Competitive Strengths and Risks
An instruments-reagents-services combined model and a diversified global customer base are strengths, while volatility in the pharmaceutical and biotech capital investment cycle is the core risk.
💪 Core Competitive Strengths
⚠️ Core Risks
🔄 Agilent Technologies Competitors and Related Stocks (Beneficiaries)
Direct global competitors among analytical instruments and life sciences peers include the life sciences mega-group names TMO and DHR, alongside the analytical instruments specialist group WAT, BIO, and MTD. Related names include the clinical diagnostics group DGX and LH, as well as the life sciences tools group ILMN, which are grouped together from adjacent clinical and genetic analysis standpoints.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc | $576.46 | +0.0% | $214.2B | 31.0 | 4.1 | 13.53% | 0.32% |
| DHR | Danaher Corp | $196.49 | -1.3% | $138.1B | 34.9 | 2.6 | 7.61% | 0.73% |
| WAT | Waters Corp | $379.48 | -1.1% | $37.3B | 48.3 | 2.4 | 5.21% | - |
 BIO | Bio-Rad Laboratories Inc | $327.25 | -1.1% | $8.8B | 53.9 | 1.3 | 2.5% | - |
 MTD | Mettler-Toledo International Inc | $1388.33 | +0.0% | $28.1B | 32.6 | - | - | - |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
 DGX | Quest Diagnostics Inc | $235.22 | -0.3% | $26.0B | 24.9 | 3.4 | 14.35% | 1.4% |
 LH | Labcorp Holdings Inc | $307.15 | -2.3% | $25.2B | 27.2 | 2.9 | 11.05% | 0.96% |
| ILMN | Illumina Inc | $194.87 | +1.0% | $29.5B | 35.4 | 11.1 | 33.82% | - |
✅ Investor Checklist for Agilent Technologies
Key points to review when investing in Agilent Technologies. The pharmaceutical and biotech capital investment cycle, reagents and services attach rate, China market variables, and capital return flow are the core variables to monitor.
| Checklist | What to Confirm | Current Status |
|---|---|---|
| 🔬 R&D Cycle | Pharmaceutical & biotech capital investment trends | Cycle recovery phase |
| 💊 Reagents & Services | Share of reagents & services revenue | Upward trend |
| 🌏 China Market | China revenue trends & policy variables | Monitoring required |
| 💰 Capital Return | Dividend increase & buyback trends | Steady return flow |
During periods of slower pharmaceutical and biotech capital investment, instrument revenue may come under pressure. Changes in China market conditions and bio policies, new product and pricing competition with analytical instruments rivals, and FX volatility should also be monitored together as short-term margin risk factors.
A core global analytical instruments name that combines the instruments-reagents-services model with a diversified global customer base. Given cyclical volatility, a dollar-cost averaging approach and a long-term perspective are recommended.
이 글은 2026년 5월 21일 기준 정보입니다.